Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arf-GAP domain and FG repeat-containing protein 2 (AGFG2) is a mammalian member of the ArfGAP protein family, containing a zinc-finger Arf-GAP domain, several phenylalanine-glycine (FG) repeats, and asparagine-proline-phenylalanine (NPF) motifs[3]. AGFG2 regulates vesicular trafficking, particularly by facilitating the stimulation-dependent exocytosis of von Willebrand factor (vWF) from Weibel–Palade bodies in endothelial cells upon exposure to phorbol ester or histamine[1][2][3]. It interacts with Eps15 homology (EH) domains and plays a role in the Rev export pathway, which mediates the nucleocytoplasmic transfer of proteins and RNAs[3]. AGFG2 is also highly expressed in the salivary gland and may contribute to exocytosis in other secretory cells. It has been identified as a host factor that influences HIV-1 progression, suggesting potential broader relevance in viral replication or immune response modulation[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arf-GAP domain and FG repeat-containing protein 2 (AGFG2).